MAZE THERAPEUTICS INC (MAZE:NASDAQ)
$25.69 -1.15 (-4.2846%)
Analysed MAZE THERAPEUTICS INC (MAZE:NASDAQ) News Sources
Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact
21-04-2026
yahoo.com
Here is why Maze Therapeutics (MAZE) is Among the Top 8 Oversold Strong Buy-Rated Stocks
08-04-2026
yahoo.com
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
04-04-2026
fool.com
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)
27-03-2026
yahoo.com
Why Maze Therapeutics Plunged 35% Despite 'Overwhelming Positive' Data
25-03-2026
yahoo.com
Maze Therapeutics Shares Phase II HORIZON Data: MZE829 Cuts Proteinuria in APOL1 Kidney Disease
25-03-2026
marketbeat.com
Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%
25-03-2026
fool.com
Maze set to target Vertex as kidney disease drug succeeds in Phase II trial
25-03-2026
clinicaltrialsarena.com
Top Midday Decliners
25-03-2026
yahoo.com
Maze tumbles despite positive data for kidney disease drug
25-03-2026
biopharmadive.com
What is the current price of MAZE THERAPEUTICS INC (MAZE:NASDAQ)?
The current price of MAZE THERAPEUTICS INC (MAZE:NASDAQ) is $25.69.
MAZE THERAPEUTICS INC (MAZE:NASDAQ) absolute price change since previous trading day?
The absolute price change of MAZE THERAPEUTICS INC (MAZE:NASDAQ) since the previous trading day is $-1.15.
MAZE THERAPEUTICS INC (MAZE:NASDAQ) percentage price change since previous trading day?
The percentage price change of MAZE THERAPEUTICS INC (MAZE:NASDAQ) since the previous trading day is -4.2846%.
What is the most recent average sentiment score for MAZE THERAPEUTICS INC (MAZE:NASDAQ)?
The most recent average sentiment score for MAZE THERAPEUTICS INC (MAZE:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for MAZE THERAPEUTICS INC (MAZE:NASDAQ)?
The most recent sentiment for MAZE THERAPEUTICS INC (MAZE:NASDAQ) is .
SEC-8K** Filing Available For MAZE THERAPEUTICS INC (MAZE:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.